Freestone Grove Partners LP Acquires Shares of 10,140 Insulet Corporation $PODD

Key Points

• Freestone Grove Partners initiated a position in Insulet, purchasing 10,140 shares valued at approximately $1.54 million. Insulet director Timothy C. Stonesifer also increased his holdings by 44.6% through an open-market purchase.
• Insulet reported strong quarterly results, with revenue up 23.5% year over year to $801.7 million and adjusted EPS of $1.66, exceeding the $1.47 analyst consensus. The company issued fiscal 2026 EPS guidance of approximately $6.46, while analysts project $6.51.
• Despite strong operating results, analyst sentiment has weakened and the stock carries legal risk. Several firms cut price targets or ratings, while securities litigation related to Omnipod device corrections has created an overhang; Insulet’s consensus rating is currently “Hold.”

Freestone Grove Partners LP bought a new position in Insulet Corporation (NASDAQ:PODD - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 10,140 shares of the medical instruments supplier's stock, valued at approximately $1,544,000.

Other institutional investors have also made changes to their positions in the company. Larson Financial Group LLC lifted its stake in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Insulet during the fourth quarter valued at $26,000. DV Equities LLC bought a new stake in Insulet during the fourth quarter valued at $28,000. Elyxium Wealth LLC acquired a new stake in shares of Insulet during the fourth quarter worth $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of Insulet during the fourth quarter worth $29,000.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction on Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director owned 9,041 shares of the company's stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.36% of the stock is owned by insiders.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest reported quarter showed strong fundamentals: revenue rose 23.5% year over year to $801.7 million, while adjusted earnings of $1.66 per share exceeded the $1.47 analyst consensus. The company has also issued fiscal 2026 earnings guidance, with analysts projecting approximately $6.51 per share. Insulet financial and trading information
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, and Robbins Geller—reminded investors that August 31, 2026 is the deadline to seek lead-plaintiff status in the securities class action. The notices generally cover purchases made between February 21, 2025 and May 26, 2026, although one complaint cites a later starting date of May 21, 2025. Rosen Insulet deadline notice
• Negative Sentiment: The litigation creates an overhang because investors allege Insulet and certain officers violated federal securities laws and seek damages. The notices reference two Omnipod medical-device corrections and a decline of more than $90 per share from pre-disclosure levels, potentially increasing concerns about product quality, disclosure practices, legal costs, and reputational risk. The allegations have not been proven. Insulet investor litigation alert

Insulet Price Performance

Shares of NASDAQ:PODD opened at $145.13 on Friday. The firm's 50 day moving average is $154.46 and its two-hundred day moving average is $181.15. The firm has a market capitalization of $10.06 billion, a P/E ratio of 27.13, a PEG ratio of 1.14 and a beta of 1.10. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same period in the previous year, the firm posted $1.17 earnings per share. The business's revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts anticipate that Insulet Corporation will post 6.51 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on PODD. Wells Fargo & Company downgraded shares of Insulet from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $255.00 to $144.00 in a research report on Wednesday, August 5th. Wall Street Zen cut shares of Insulet from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 9th. Bank of America decreased their target price on Insulet from $288.00 to $208.00 and set a "buy" rating for the company in a research note on Monday, May 18th. Barclays lowered their target price on Insulet from $286.00 to $198.00 and set an "underweight" rating for the company in a report on Thursday, May 7th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and issued a $152.00 price target (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Insulet presently has an average rating of "Hold" and a consensus price target of $195.40.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.